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Abstract
Microvesicles are able to induce the cell of origin’s phenotype in a target cell. MicroRNA-21, as an oncomir, is
up-regulated in almost all cancer types such as leukemia which results in cell proliferation. In this study, we examine
the ability of leukemia microvesicles to induce proliferation in hematopoietic stem progenitor cells (HSPCs) via
microRNA-21 dysregulation. Herein, leukemia microvesicles were isolated from HL-60 and NB-4 cell lines by ultra-
centrifugation, and then their protein content was measured. Normal HSPCs were isolated from umbilical cord blood
samples by a CD-34 antibody. These cells were treated with 20 and 40 g/mL leukemia microvesicles for 5 and 10
days, respectively. Cell count, CD-34 analysis, and a microRNA-21 gene expression assay were done at days 5 and
10. HSPCs showed a significant increase in both microRNA-21 gene expression and cell count after treating with leu-
kemia microvesicles compared with the control group. CD-34 analysis as stemness proof did not show any differ-
ence among the studied groups. This data suggests that HSPC proliferation followed by microRNA-21 gene over
expression can be another evidence of a leukemia-like phenotype induction in a healthy target cell by leukemia
microvesicles.
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Introduction
Microvesicles, membrane-derived sacs, are shed
from a variety of cell types including both normal and ab-
normal cells under physiological or pathological condition
(D’Souza-Schorey et al., 2012). They promote communi-
cation between the cells and surrounding environments
based on their cargo which depends on the cell of origin
(Muralidharan-Chari et al., 2010). Microvesicles carry
both mRNAs and microRNAs, which can be transferred be-
tween cells as genetic materials (Lee et al., 2012), and
transform the target cell’s phenotype according to the cell
of origin (Jang et al., 2004; Aliotta et al., 2007; Renzulli et
al., 2010). As they originate from a tumor cell, they contain
its molecular signatures and operate intercellular communi-
cation based on this information (Martins et al., 2013). So it
seems likely that tumor cell microvesicles are able to
change a healthy cell’s phenotype and induce some tumor
signatures.
MicroRNA-21, a short non-coding RNA, is the only
microRNA up-regulated in all human malignancies and is
involved in tumorigenesis, progression and metastasis (Vo-
linia et al., 2006; Panet al., 2010). Also, it shows higher
expression in leukemic stem cells (LSCs) than in hemato-
poietic stem cells (HSCs) (Martianez Canales et al., 2017).
This microRNA plays a pivotal role in tumor cell prolifera-
tion via different target genes, and cell cycle arrest and
apoptosis occur while its expression is inhibited (Chan et
al., 2005; Li et al., 2009; Yao et al., 2009).
Acute myeloid leukemia (AML) is defined by defects
in the differentiation of hematopoietic stem and progenitor
cells in the bone marrow, which transform a healthy HSC
into a LSC (Aberger et al., 2017). One of the first modifica-
tions in a LSC is an uncontrolled cell cycle and higher rate
of proliferation, resulting in the accumulation of mutations
and therefore, the first step for leukemogenesis (Schnerch
et al., 2012).
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While normal and leukemic cells exist in the same
microenvironment, leukemia microvesicles are probably
able to perform a cross-talk between cells and affect them.
In this study, using leukemia microvesicles, we report alter-
ations in the proliferation and microRNA-21 gene expres-
sion in healthy HSPCs as two important signatures of
leukemia.
Material and Methods
Cell preparation
Leukemia cell lines (HL-60 and NB-4) were cultured
in RPMI 1640 medium containing 20% fetal bovine serum
(FBS) (for HL-60 cell line) and 10% FBS (for NB-4 cell
line), 100 U/mL Penicillin and 100 g/mL Streptomycin at
37 °C, 5% CO2 and at least 90% humidity to obtain enough
cells for microvesicles isolation.
Microvesicle isolation and characterization
Once enough cells were obtained, they were main-
tained (separately) in RPMI 1640 medium containing 0.6%
bovine serum albumin (BSA), 100 U/mL Penicillin and 100
g/mL Streptomycin at 37 °C, 5% CO2 and at least 90% hu-
midity overnight. The day after, cells supernatant was col-
lected for microvesicle isolation and purification by
ultra-centrifugation (Razmkhah et al., 2015). Briefly, the
cell supernatant was centrifuged stepwise at 2000, 10,000
and 20,000 x g to exclude cells (live and dead), cell debris
and exosomes respectively. The final centrifugation at
20,000 x g was repeated to achieve a pure microvesicles
pellet. Quality of isolated microvesicles was assessed by
transmission electron microscopy (TEM) using negative
staining by 2% uranyl acetate for 30s. A Bradford assay
was done to measure the microvesicles’ protein concentra-
tion, and then they were used freshly to treat sorted HSPCs.
HSPC sorting
Umbilical cord blood samples collected in CPDA1
reagent from healthy donors were received from the Iranian
Blood Transfusion Organization (IBTO) cord blood bank
after written consent was obtained. Mononuclear cells
(MNCs) were isolated by Lymphoprep (Stemcell Technol-
ogies, Vancouver, Canada) and then used to sort HSPCs by
CD-34 magnetic immunobeads (Milteny Biotec, Auburn,
CA) according to the manufacturer’s instructions.
Treating HSPCs with leukemia microvesicles
Sorted HSPCs were divided into 5 groups (55,000
cells in each group) for treatment: 1- without any micro-
vesicles (as control group), 2- with 20 and 40 g/mL HL-60
microvesicles (as H-20 and H-40 groups), 3- with 20 and 40
g/mL NB-4 microvesicles (as N-20 and N-40 groups).
The cells were kept in 500 L Stemline medium (Sigma-
Aldrich, St Louis, MO) containing 50 ng/mL of Thrombo-
poietin (TPO; PeproTech, London, UK) and Fms-like tyro-
sine kinase 3 (FLT3; ORF Genetics, Kopavogur, Iceland)
recombinant growth factors for 5 and 10 days. HSPCs were
treated with leukemia microvesicles only once at day 0. No
more microvesicle were added later.
Cell count
After washing cells in phosphate-buffered saline
(PBS) and staining them with Trypan Blue, viable cells
were counted in a hemocytometer at days 5 and 10.
CD-34 analysis
Washed cells were stained by CD-34 antibody (PE-
eBioscience, USA) to evaluate this HSPC specific marker
at day 0 as purity index, and at days 5 and 10 as stemness
marker.
microRNA-21 gene expression
Washed cells (without any microvesicles) were used
for total RNA extraction by RNX Plus reagent (CinnaGen,
Iran). Complementary DNAs (cDNAs) for microRNA-21
and Snord47 were then specifically synthesized according
to the manufacturer’s instructions (ThermoFisher Scien-
tific, Waltham, MA USA) using stem loop primers
(Mohammadi-Yeganeh et al., 2013), as shown in Table 1.
Quantitative real-time polymerase chain reaction (PCR)
was performed to evaluate microRNA-21 gene expression
fold change in an Applied Biosystems StepOne real-time
system (Applied Biosystems, Foster City, CA, USA) using
SYBR Green PCR master mix (TaKaRa, Japan) and spe-
cific primers (Table 1). The raw reads were normalized
with Snord 47 and relative expression was calculated ac-
cording to Ct method.
Statistical analysis
Results from three different experiments were statis-
tically analyzed using SPSS 22 (Microsoft, Chicago, IL,
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Table 1 - Primer sequences.
Gene name Primer sequence (RT) Primer sequence (Real Time PCR)
microRNA-21 GTC GTA TGC AGA GCA GGG TCC GAG GTA TTC
GCA CTG CAT ACG ACT CAA CA
F- CGC CGT AGC TTA TCA GAC T
R- GAG CAG GGT CCG AGG T
Snord 47 GTC GTA TGC AGA GCA GGG TCC GAG GTA TTC
GCA CTG CAT ACG ACA ACC TC
F- ATC ACT GTA AAA CCG TTC CA
R- GAG CAG GGT CCG AGG T
USA). One way ANOVA was applied for comparing
means among groups, and Tukey tests were done to find
significant different between groups. Pearson’s test was ap-
plied to assay any correlation between the studied vari-
ables. An adjusted significance level less than 0.05 was
considered statistically significant.
Results
Microvesicle quality control
Isolated microvesicles were qualitatively assessed by
TEM as proof of the isolation protocol by showing the ex-
pected size of microvesicles (Figure 1). Also, the integrity
of the microvesicles’ membrane was completely main-
tained during the different stages of isolation as shown in
Figure 1. Hence, these microvesicles are suitable for treat-
ing healthy HSPCs.
Cell proliferation
HSPCs were counted after being treated with differ-
ent amounts of microvesicles originated from the HL-60
and NB-4 lines. A significant increase in HSPCs number
was observed after treatment with 20 and 40 g/mL HL-60
and NB-4 microvesicles (p<0.001) compared with the re-
spective control groups at days 5 and 10 (Figures 2 and 3).
In addition, the cell count in the control groups decreased
during these 10 days. No change in the morphology of
HSPCs was observed at the different time points.
HSPC marker
A CD34 antigen assay as HSPC-specific marker and
stemness marker was performed using flow cytometry
(Figure 4) which showed a high level in HSPCs after treat-
ment with 20 and 40 g/mL HL-60 and NB-4 microvesicles
compared to control groups at day 0 (Figure 5).
microRNA-21 gene expression
Quantitative Real Time PCR data revealed a signifi-
cant overexpression of microRNA-21 gene in HSPCs after
treatment with 20 and 40 g/mL HL-60 and NB-4 micro-
vesicles (p<0.001) compared with control groups at day 10
(Figure 6). No significant difference in microRNA-21 gene
expression was observed among groups at day 5.
Correlation test
The Spearman test showed a strong correlation be-
tween cell count and microRNA-21 gene expression in
HSPCs treated with 20 and 40 g/mL HL-60 microvesicles
at day 5 (correlation coefficient = 0.742, p= 0.02) and day
10 (correlation coefficient= 0.965, p<0.001). Also, a posi-
tive correlation was observed between cell count and
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Figure 1 - Transmission electron microscopy image of isolated micro-
vesicles. The maximum size of microvesicles is 1 m in diameter. No
damage is observed in microvesicles’ membrane.
Figure 2 - HSPC counts. A) HSPC counts after treatment with 20 and 40 g/mL HL-60 microvesicles. B) HSPC counts after treatment with 20 and 40
g/mL NB-4 microvesicles. (H: HL-60 microvesicles, N: NB-4 microvesicles) ** p<0.001.
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Figure 3 - Increased number of HSPCs after treatment with leukemia microvesicles (400X). A) HSPCs at day 5. B) HSPCs at day 10.
Figure 4 - CD34 analysis. A) HSPCs gate. B) Isotype control (red histogram) and CD-34 positive cells (blue histogram).
Figure 5 - HSPC CD34 antigen assay (percentage). A) After treatment with 20 and 40 g/mL HL-60 microvesicles. B) After treatment with 20 and 40
g/mL NB-4 microvesicles.
microRNA-21 gene expression in HSPCs treated with 20
and 40 g/mL NB-4 microvesicles at day 5 (correlation co-
efficient= 0.854, p= 0.003) and day 10 (correlation coeffi-
cient= 0.962, p<0.001).
Discussion
Microvesicles are important transporters of genetic
information and play a key role in disease spread by tumor
cell/normal cell interactions (Baj-Krzyworzeka et al.,
2006; Martins et al., 2013; Fujita et al., 2016). This para-
crine signaling is common in a tumor microenvironment
where tumor and normal cells are close to each other. Also,
tumor cells can adopt an aggressive phenotype, a result of
their interaction with other tumor cells via microvesicles
(Al-Nedawi et al., 2008).
In this study, we designed an experiment with a small
community of leukemia microvesicles and healthy HSPCs
to show interactions that indicate transformation of HSPCs
as a target cell type. HL-60 and NB-4 cell lines were se-
lected for this study, both of which belong to M3 subtype of
AML, one without translocation (HL-60) and the other with
translocation t(15:17)(NB-4). Leukemia microvesicles
were isolated from them and were used to treat healthy
HSPCs at doses of 20 and 40 g/mL for 5 days and 10 days.
As an important point, we did not use SCF growth factor in
the HSPCs culture media to avoid and eliminate its prolifer-
ation effect. Although this resulted in cell death and count
decrease in control groups (groups without microvesicles),
it helped us to explore the role of leukemia microvesicles in
the cell proliferation of the other groups (groups with
microvesicles). Surprisingly, higher numbers of HSPCs
were observed in the different experimental groups than in
their control groups.
We previously reported that 30 g/mL leukemic bone
marrow derived microvesicles (non-M3 subtypes of AML)
permit the survival of healthy HSPCs until day 7 compared
with control groups (Razmkhah et al., 2017). We also
showed that 20 g/mL microvesicles from the Jurkat cell
line (T-ALL) induce survival in healthy HSPC until day 7
(Razmkhah et al., 2015). The current study also showed
that M3 microvesicles can induce survival in healthy
HSPCs, like non-M3 and T-ALL microvesicles, even until
day 10. This finding is of interest as the low dose of leuke-
mia microvesicles (20 and 30 g/mL) promoted survival
and the higher dose (40 g/mL) stimulated proliferation in
healthy HSPCs. Ghosh et al. (2010) showed that B cell
chronic lymphoblastic leukemia (B-CLL) derived micro-
vesicles are able to activate and sustain activated AKT sig-
naling in bone marrow stromal cells to produce vascular
endothelial growth factor (VEGF) as a survival factor for
CLL B cells. Another study showed that chronic myelo-
blastic leukemia (CML) derived exosome (another extra-
cellular vesicle with smaller size than microvesicles) can
promote both survival and proliferation of CML cells
through an autocrine mechanism by a ligand-receptor inter-
action between TGF-1, found in CML-derived exosomes,
and the TGF- 1 receptor on CML cells. (Raimondo et al.,
2015) Moreover, Wang et al. (2016) found that LSC de-
rived microvesicles prevent apoptosis and induce survival
in AML cells associated with microRNA-34 deficit. Also,
Skog et al. (2008) concluded that glioblastoma micro-
vesicles stimulate proliferation of a human glioma cell.
These studies indicate that tumor cell derived micro-
vesicles can potentially change their environment to pro-
vide a better situation for survival and proliferation, or
increase the survival of adjacent tumor cells for disease
progression.
MicroRNA-21, an oncogenic microRNA, affects the
expression of multiple tumor suppressor genes, such as
Phosphatase and Tensin homolog (PTEN), Serpini1, and
programmed cell death protein 4 (PDCD4), which results in
cell growth and proliferation (Sekar et al., 2016). This
microRNA is also up-regulated in numerous cancer stem
cells (CSCs) (Sekar et al., 2016) such as LSCs, but not in
healthy HSPCs (Martianez Canales et al., 2017). By inhib-
iting microRNA-21 in myeloid cell lines, such as HL60 and
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Figure 6 - microRNA-21 gene expression in HSPCs after treating with A) 20 and 40 g/mL HL-60 microvesicles and B) 20 and 40 g/mL NB-4
microvesicles. ** p<0.001.
K562, reduced cell growth, induced apoptosis and in-
creased sensitivity to different chemotherapeutic agents
were observed, providing support for the role of this
microRNA in leukemia progression (Hu et al., 2010; Li et
al., 2010; Bai et al., 2011; Gu et al., 2011). Medina and col-
leagues showed that miR-21 over-expression alone leads to
a pre-B malignant lymphoid-like phenotype in a mouse
model, which was regressed completely when micro-
RNA-21 was inactivated (Medina et al., 2010). This is a
clear evidence that microRNA-21 is able to uniquely trans-
form a healthy HSPC to express a malignant phenotype. In
the current study, we found about a 10 and 15 times in-
crease in microRNA-21 gene expression in healthy HSPCs
after treatment with 40 g/mL leukemia microvesicles
from HL-60 and NB-4 cell lines, respectively. This is di-
rectly correlated with cell count (p<0.001), which shows
the expected role of microRNA-21 in cell survival and pro-
liferation. After 10 days of culture, HSPCs still express
more than 70% CD-34 antigen, which proves they are still
stem cells. Hence, microRNA-21 over-expression and in-
creased cell proliferation happened in a stem cell. This new
stem cell with higher proliferation and microRNA-21 gene
expression is now different from the control group.
In the bone marrow of patients with acute myeloid
leukemia, leukemia cells occupy all the bone marrow
microenvironment. But few healthy HSPCs still exist in the
neighborhood of leukemia cells. As a rule, cancer cells pro-
duce huge amounts of microvesicles due to their high rate
of proliferation (Ginestra et al., 1998). These microvesicles
can now penetrate to an adjacent cell, which can be a
healthy HSPC, and transform it by increasing microRNA-
21 gene expression and promote high proliferation. This
can also occur in an adjacent leukemia cell to induce more
proliferation than before. In addition, once remission is
achieved, LSCs that are resistant to current chemothera-
pies, still exist in the bone marrow and are able to prolifer-
ate and differentiate to leukemia blasts. These few leuke-
mia cells now produce microvesicles and can affect
adjacent healthy cells to express microRNA-21 gene, re-
sulting in high proliferation and an increase in the speed of
relapse.
Therefore, leukemia microvesicles in a leukemic
microenvironment, wherein normal and malignant cells are
close to each other, are potentially able to transfer some
phenotypes of leukemia, such as high proliferation between
cells and result in disease progression. Moreover, they can
transform the genotype of target cells to express higher rate
of an oncomir, microRNA-21, to have a continuous prolif-
eration like a leukemia cell. So, this mechanism of disease
progression should be inhibited by blocking microvesicle
production in leukemia cells to clinically improve the che-
motherapy results and decrease the rate of relapse.
In conclusion, we found relevant changes in a healthy
HSPC after treatment with leukemia microvesicles, which
promotes a leukemia-like phenotype and provides evidence
of potential disease spread in a leukemic microenviron-
ment.
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